[Mental disorders and diabetes mellitus (Update 2023)].
Psychische und neurokognitive Erkrankungen und Diabetes mellitus (Update 2023).
Anxiety disorders
Depression
Diabetes mellitus
Mental disorders
Schizophrenia
Journal
Wiener klinische Wochenschrift
ISSN: 1613-7671
Titre abrégé: Wien Klin Wochenschr
Pays: Austria
ID NLM: 21620870R
Informations de publication
Date de publication:
Jan 2023
Jan 2023
Historique:
accepted:
09
11
2022
medline:
28
4
2023
pubmed:
27
4
2023
entrez:
26
4
2023
Statut:
ppublish
Résumé
Psychiatric disorders and psychological problems are common in patients with diabetes mellitus. There is a twofold increase in depression which is associated with suboptimal glycemic control and increased morbidity and mortality. Other psychiatric disorders with a higher incidence of diabetes are cognitive impairment, dementia, disturbed eating behavior, anxiety disorders, schizophrenia, bipolar disorders and borderline personality disorder. The coincidence of mental disorders and diabetes has unfavorable influences on metabolic control and micro- and macroangiopathic complications. Improvement of therapeutic outcome is a challenge in the modern health care system. The intentions behind this position paper are to rise awareness of this special set of problems, to intensify cooperation between involved health care providers and to reduce incidence of diabetes mellitus as well as morbidity and mortality from diabetes in this patient group. Diabetes mellitus ist häufig mit psychischen Erkrankungen assoziiert. Depressive Störungen kommen bei diabetischen Patient:innen doppelt so häufig vor wie in der nicht-diabetischen Population. Andere psychische Erkrankungen, die gehäuft mit Prädiabetes und Diabetes mellitus vorkommen, sind kognitive Dysfunktionen bis zur Demenz, auffälliges Essverhalten, Angststörungen, Schizophrenie, bipolare Störungen und Borderline-Persönlichkeitsstörungen. Die ungünstigen Auswirkungen dieser Koinzidenz auf den Stoffwechsel sind nachhaltig und manifestieren als schlechtere metabolische Kontrolle und vermehrte mikro- und makroangiopathische Komplikationen. Ziel dieses Positionspapieres ist die Sensibilisierung aller involvierten medizinischen Fachkolleg:innen sowie aller anderen mit dem Thema Diabetes befassten Berufsgruppen und Organisationen, um eine Intensivierung der komplexen therapeutischen Interventionen bei Patient:innen zu erreichen.Positive Auswirkungen wären die Verringerung der Inzidenz von Diabetes mellitus bei Patient:innen mit psychischen Erkrankungen, sowie die Reduktion von Spätfolgen des Diabetes mellitus, insbesondere der kardiovaskulären Morbidität und Mortalität und eine verbesserte Lebensqualität der Betroffenen.
Autres résumés
Type: Publisher
(ger)
Diabetes mellitus ist häufig mit psychischen Erkrankungen assoziiert. Depressive Störungen kommen bei diabetischen Patient:innen doppelt so häufig vor wie in der nicht-diabetischen Population. Andere psychische Erkrankungen, die gehäuft mit Prädiabetes und Diabetes mellitus vorkommen, sind kognitive Dysfunktionen bis zur Demenz, auffälliges Essverhalten, Angststörungen, Schizophrenie, bipolare Störungen und Borderline-Persönlichkeitsstörungen. Die ungünstigen Auswirkungen dieser Koinzidenz auf den Stoffwechsel sind nachhaltig und manifestieren als schlechtere metabolische Kontrolle und vermehrte mikro- und makroangiopathische Komplikationen. Ziel dieses Positionspapieres ist die Sensibilisierung aller involvierten medizinischen Fachkolleg:innen sowie aller anderen mit dem Thema Diabetes befassten Berufsgruppen und Organisationen, um eine Intensivierung der komplexen therapeutischen Interventionen bei Patient:innen zu erreichen.Positive Auswirkungen wären die Verringerung der Inzidenz von Diabetes mellitus bei Patient:innen mit psychischen Erkrankungen, sowie die Reduktion von Spätfolgen des Diabetes mellitus, insbesondere der kardiovaskulären Morbidität und Mortalität und eine verbesserte Lebensqualität der Betroffenen.
Identifiants
pubmed: 37101044
doi: 10.1007/s00508-022-02117-9
pii: 10.1007/s00508-022-02117-9
pmc: PMC10133031
doi:
Types de publication
English Abstract
Journal Article
Langues
ger
Sous-ensembles de citation
IM
Pagination
225-236Informations de copyright
© 2023. The Author(s).
Références
Young-Hyman D, de Groot M, Hill-Briggs F, et al. Psychosocial care for people with diabetes: a position statement of the American diabetes association. Diabetes Care. 2016;39(12):2126–40. https://doi.org/10.2337/dc16-2053 .
doi: 10.2337/dc16-2053
pubmed: 27879358
pmcid: 5127231
De Hert M, Dobbelaere M, Sheridan EM, et al. Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: a systematic review of randomized, placebo controlled trials and guidelines for clinical practice. Eur Psychiatry. 2011;26(3):144–58. https://doi.org/10.1016/j.eurpsy.2010.09.011 .
doi: 10.1016/j.eurpsy.2010.09.011
pubmed: 21295450
Smith M, Hopkins D, Peveler RC, et al. First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis. Br J Psychiatry. 2008;192(6):406–11. https://doi.org/10.1192/bjp.bp.107.037184 .
doi: 10.1192/bjp.bp.107.037184
pubmed: 18515889
De Hert M, Dekker JM, Wood D, et al. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European psychiatric association (EPA), supported by the European association for the study of diabetes (EASD) and the European society of cardiology (ESC). Eur Psychiatry. 2009;24(6):412–24.
doi: 10.1016/j.eurpsy.2009.01.005
pubmed: 19682863
Today Study Group. Longitudinal association of depressive symptoms, binge eating, and quality of life with cardiovascular risk factors in young adults with youth-onset type 2 diabetes: the TODAY2 study. Diabetes Care. 2022; https://doi.org/10.2337/dc21-1995 .
doi: 10.2337/dc21-1995
Fisher L, Hessler DM, Polonsky WH, et al. When is diabetes distress clinically meaningful?: establishing cut points for the diabetes distress scale. Diabetes Care. 2012;35(2):259–64. https://doi.org/10.2337/dc11-1572 .
doi: 10.2337/dc11-1572
pubmed: 22228744
pmcid: 3263871
American Diabetes Association. (4) Foundations of care: education, nutrition, physical activity, smoking cessation, psychosocial care, and immunization. Diabetes Care. 2015;38:S20–30. https://doi.org/10.2337/dc15-S007 .
doi: 10.2337/dc15-S007
Welch G, Weinger K, Anderson B, et al. Responsiveness of the problem areas in diabetes (PAID) questionnaire. Diabet Med. 2003;20(1):69–72. https://doi.org/10.1046/j.1464-5491.2003.00832.x .
doi: 10.1046/j.1464-5491.2003.00832.x
pubmed: 12519323
Polonsky WH, Fisher L, Earles J, et al. Assessing psychosocial distress in diabetes: development of the diabetes distress scale. Diabetes Care. 2005;28(3):626–31. https://doi.org/10.2337/diacare.28.3.626 .
doi: 10.2337/diacare.28.3.626
pubmed: 15735199
Katon W, Fan MY, Unützer J, et al. Depression and diabetes: a potentially lethal combination. J Gen Intern Med. 2008;23(10):1571–5. https://doi.org/10.1007/s11606-008-0731-9 .
doi: 10.1007/s11606-008-0731-9
pubmed: 18649108
pmcid: 2533367
Sullivan MD, O’Connor P, Feeney P, et al. Depression predicts all-cause mortality: epidemiological evaluation from the ACCORD HRQL substudy. Diabetes Care. 2012;35(8):1708–15. https://doi.org/10.2337/dc11-1791 .
doi: 10.2337/dc11-1791
pubmed: 22619083
pmcid: 3402260
Anderson RJ, Freedland KE, Clouse RE, et al. The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes Care. 2001;24(6):1069–78.
doi: 10.2337/diacare.24.6.1069
pubmed: 11375373
Abrahamian H, Hofmann P, Prager R, et al. Diabetes mellitus and co-morbid depression: treatment with milnacipran results in significant improvement of both diseases (results from the Austrian MDDM study group). Neuropsychiatr Dis Treat. 2009;5:261–6. https://doi.org/10.2147/ndt.s5421 .
doi: 10.2147/ndt.s5421
pubmed: 19557120
pmcid: 2695229
Knol MJ, Twisk JW, Beekman AT, et al. Depression as a risk factor for the onset of type 2 diabetes mellitus. A meta-analysis. Diabetologia. 2006;49(5):837–45. https://doi.org/10.1007/s00125-006-0159-x .
doi: 10.1007/s00125-006-0159-x
pubmed: 16520921
Ali S, Stone MA, Peters JL, et al. The prevalence of co-morbid depression in adults with Type 2 diabetes: a systematic review and meta-analysis. Diabet Med. 2006;23(11):1165–73. https://doi.org/10.1111/j.1464-5491.2006.01943.x .
doi: 10.1111/j.1464-5491.2006.01943.x
pubmed: 17054590
Franciosi M, Lucisano G, Lapice E, et al. Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review. PLoS One. 2013;8(8):e71583. https://doi.org/10.1371/journal.pone.0071583 .
doi: 10.1371/journal.pone.0071583
pubmed: 23936520
pmcid: 3732236
Gonzalez JS, Delahanty LM, Safren SA, et al. Differentiating symptoms of depression from diabetes-specific distress: relationships with self-care in type 2 diabetes. Diabetologia. 2008;51(10):1822–5.
doi: 10.1007/s00125-008-1113-x
pubmed: 18690422
pmcid: 2678064
Whooley MA, Avins AL, Miranda J, et al. Case-finding instruments for depression. Two questions are as good as many. J Gen Intern Med. 1997;12(7):439–45. https://doi.org/10.1046/j.1525-1497.1997.00076.x .
doi: 10.1046/j.1525-1497.1997.00076.x
pubmed: 9229283
pmcid: 1497134
Hautzinger M, Keller F, Kühner C. Beck Depressions-Inventar (BDI-II). Revision. Frankfurt am Main: Harcourt Test Services; 2006.
Herrmann-Lingen C, Buss U, Snaith RP. HADS‑D. Hospital anxiety and depression scale. 3. Aufl. Bern: Huber; 2011. Deutsche Version.
Gregory JM, Rosenblat JD, McIntyre RS. Deconstructing diabetes and depression: clinical context, treatment strategies, and new directions. Focus (Am Psychiatr Publ). 2016;14(2):184–93. https://doi.org/10.1176/appi.focus.20150040 .
doi: 10.1176/appi.focus.20150040
pubmed: 31975802
Petrak F, Baumeister H, Skinner TC, et al. Depression and diabetes: treatment and health-care delivery. Lancet Diabetes Endocrinol. 2015;3(6):472–85. https://doi.org/10.1016/S2213-8587(15)00045-5 .
doi: 10.1016/S2213-8587(15)00045-5
pubmed: 25995125
Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018;391(10128):1357–66. https://doi.org/10.1016/S0140-6736(17)32802-7 .
doi: 10.1016/S0140-6736(17)32802-7
pubmed: 29477251
pmcid: 5889788
Dodd S, Mitchell PB, Bauer M, et al. Monitoring for antidepressant-associated adverse events in the treatment of patients with major depressive disorder: an international consensus statement. World J Biol Psychiatry. 2018;19(5):330–48. https://doi.org/10.1080/15622975.2017.1379609 .
doi: 10.1080/15622975.2017.1379609
pubmed: 28984491
Correll CU, Detraux J, De Lepeleire J, et al. Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World Psychiatry. 2015;14(2):119–36. https://doi.org/10.1002/wps.20204 .
doi: 10.1002/wps.20204
pubmed: 26043321
pmcid: 4471960
Demyttenaere K, Corruble E, Hale A, et al. A pooled analysis of six month comparative efficacy and tolerability in four randomized clinical trials: agomelatine versus escitalopram, fluoxetine, and sertraline. CNS Spectr. 2013;18(3):163–70. https://doi.org/10.1017/S1092852913000060 .
doi: 10.1017/S1092852913000060
pubmed: 23472671
Liu CS, Carvalho AF, McIntyre RS. Towards a „metabolic“ subtype of major depressive disorder: shared pathophysiological mechanisms may contribute to cognitive dysfunction. CNS Neurol Disord Drug Targets. 2014;13(10):1693–707. https://doi.org/10.2174/1871527313666141130204031 .
doi: 10.2174/1871527313666141130204031
pubmed: 25470395
Kashani L, Omidvar T, Farazmand B, et al. Does pioglitazone improve depression through insulin-sensitization? Results of a randomized double-blind metformin-controlled trial in patients with polycystic ovarian syndrome and comorbid depression. Psychoneuroendocrinology. 2013;38(6):767–76. https://doi.org/10.1016/j.psyneuen.2012.08.010 .
doi: 10.1016/j.psyneuen.2012.08.010
pubmed: 22999261
Tabak AG, Akbaraly TN, Batty GD, et al. Depression and type 2 diabetes: a causal association? Lancet Diabetes Endocrinol. 2014;2(3):236–45. https://doi.org/10.1016/S2213-8587(13)70139-6 .
doi: 10.1016/S2213-8587(13)70139-6
pubmed: 24622754
Darwish L, Beroncal E, Sison MV, et al. Depression in people with type 2 diabetes: current perspectives. Diabetes Metab Syndr Obes. 2018;11:333–43. https://doi.org/10.2147/DMSO.S106797 .
doi: 10.2147/DMSO.S106797
pubmed: 30022843
pmcid: 6044353
Ress C, Tschoner A, Kaser S, et al. Psychopharmaka und Diabetes. Wien Med Wochenschr. 2011;161(21):531–42. https://doi.org/10.1007/s10354-011-0004-9 .
doi: 10.1007/s10354-011-0004-9
pubmed: 21792529
Collins MM, Corcoran P, Perry IJ. Anxiety and depression symptoms in patients with diabetes. Diabet Med. 2009;26(2):153–61. https://doi.org/10.1111/j.1464-5491.2008.02648.x .
doi: 10.1111/j.1464-5491.2008.02648.x
pubmed: 19236618
Ludman E, Katon W, Russo J, et al. Panic episodes among patients with diabetes. Gen Hosp Psychiatry. 2006;28(6):475–81. https://doi.org/10.1016/j.genhosppsych.2006.08.004 .
doi: 10.1016/j.genhosppsych.2006.08.004
pubmed: 17088162
Young-Hyman DL, Davis CL. Disordered eating behavior in individuals with diabetes: importance of context, evaluation, and classification. Diabetes Care. 2010;33(3):683–9. https://doi.org/10.2337/dc08-1077 .
doi: 10.2337/dc08-1077
pubmed: 20190297
pmcid: 2827531
Markowitz JT, Butler DA, Volkening LK, et al. Brief screening tool for disordered eating in diabetes: internal consistency and external validity in a contemporary sample of pediatric patients with type 1 diabetes. Diabetes Care. 2010;33(3):495–500. https://doi.org/10.2337/dc09-1890 .
doi: 10.2337/dc09-1890
pubmed: 20032278
Kahl KG, Greggersen W, Schweiger U, et al. Prevalence of the metabolic syndrome in patients with borderline personality disorder: results from a cross-sectional study. Eur Arch Psychiatry Clin Neurosci. 2013;263(3):205–13. https://doi.org/10.1007/s00406-012-0339-2 .
doi: 10.1007/s00406-012-0339-2
pubmed: 22777277
Mai Q, Holman CD, Sanfilippo FM, et al. Mental illness related disparities in diabetes prevalence, quality of care and outcomes: a population-based longitudinal study. BMC Med. 2011;9:118. https://doi.org/10.1186/1741-7015-9-118 .
doi: 10.1186/1741-7015-9-118
pubmed: 22044777
pmcid: 3215928
Goff DC, Sullivan LM, McEvoy JP, et al. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res. 2005;80(1):45–53. https://doi.org/10.1016/j.schres.2005.08.010 .
doi: 10.1016/j.schres.2005.08.010
pubmed: 16198088
Jones BJ, Gallagher BJ, Moss DM, et al. Obstetrical complications, social class and type of schizophrenia. Clin Schizophr Relat Psychoses. 2011;5(1):33–9. https://doi.org/10.3371/CSRP.5.1.5 .
doi: 10.3371/CSRP.5.1.5
pubmed: 21459737
Beumer W, Drexhage RC, De Wit H, et al. Increased level of serum cytokines, chemokines and adipokines in patients with schizophrenia is associated with disease and metabolic syndrome. Psychoneuroendocrinology. 2012;37(12):1901–11. https://doi.org/10.1016/j.psyneuen.2012.04.001 .
doi: 10.1016/j.psyneuen.2012.04.001
pubmed: 22541717
Mizuki Y, Sakamoto S, Okahisa Y, et al. Mechanisms underlying the comorbidity of schizophrenia and type 2 diabetes mellitus. Int J Neuropsychopharmacol. 2021;24(5):367–82. https://doi.org/10.1093/ijnp/pyaa097 .
doi: 10.1093/ijnp/pyaa097
pubmed: 33315097
Cukierman T, Gerstein HC, Williamson JD. Cognitive decline and dementia in diabetes—systematic overview of prospective observational studies. Diabetologia. 2005;48(12):2460–9. https://doi.org/10.1007/s00125-005-0023-4 .
doi: 10.1007/s00125-005-0023-4
pubmed: 16283246
Seaquist ER. The final frontier: how does diabetes affect the brain? Diabetes. 2010;59(1):4–5. https://doi.org/10.2337/db09-1600 .
doi: 10.2337/db09-1600
pubmed: 20040482
pmcid: 2797942
The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group, Jacobson AM, Musen G, et al. Long-term effect of diabetes and its treatment on cognitive function. N Engl J Med. 2007;356(18):1842–52. https://doi.org/10.1056/NEJMoa066397 .
doi: 10.1056/NEJMoa066397
Hershey T, Perantie DC, Wu J, et al. Hippocampal volumes in youth with type 1 diabetes. Diabetes. 2010;59(1):236–41. https://doi.org/10.2337/db09-1117 .
doi: 10.2337/db09-1117
pubmed: 19833895
Launer LJ, Miller ME, Williamson JD, et al. Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. Lancet Neurol. 2011;10(11):969–77. https://doi.org/10.1016/S1474-4422(11)70188-0 .
doi: 10.1016/S1474-4422(11)70188-0
pubmed: 21958949
pmcid: 3333485
Bushe CJ, Leonard BE. Blood glucose and schizophrenia: a systematic review of prospective randomized clinical trials. J Clin Psychiatry. 2007;68(11):1682–90.
doi: 10.4088/JCP.v68n1107
pubmed: 18052561
Prisciandaro JJ, Gebregziabher M, Grubaugh AL, et al. Impact of psychiatric comorbidity on mortality in veterans with type 2 diabetes. Diabetes Technol Ther. 2011;13(1):73–8. https://doi.org/10.1089/dia.2010.0092 .
doi: 10.1089/dia.2010.0092
pubmed: 21175275
pmcid: 3025763
Zhang ZJ, Yao ZJ, Liu W, et al. Effects of antipsychotics on fat deposition and changes in leptin and insulin levels. Magnetic resonance imaging study of previously untreated people with schizophrenia. Br J Psychiatry. 2004;184:58–62. https://doi.org/10.1192/bjp.184.1.58 .
doi: 10.1192/bjp.184.1.58
pubmed: 14702228
Funnell MM, Anderson RM. The problem with compliance in diabetes. JAMA. 2000;284(13):1709.
doi: 10.1001/jama.284.13.1709-JMS1004-6-1
pubmed: 11015809
Delamater AM. Improving patient adherence. Clin Diabetes. 2006;24(2):71–7. https://doi.org/10.2337/diaclin.24.2.71 .
doi: 10.2337/diaclin.24.2.71
Norris SL, Engelgau MM, Narayan KM. Effectiveness of self-management training in type 2 diabetes: a systematic review of randomized controlled trials. Diabetes Care. 2001;24(3):561–87. https://doi.org/10.2337/diacare.24.3.561 .
doi: 10.2337/diacare.24.3.561
pubmed: 11289485
Chatterjee JS. From compliance to concordance in diabetes. J Med Ethics. 2006;32(9):507–10. https://doi.org/10.1136/jme.2005.012138 .
doi: 10.1136/jme.2005.012138
pubmed: 16943329
pmcid: 2563412
Roberts SE, Goldacre MJ, Neil HA. Mortality in young people admitted to hospital for diabetes: database study. BMJ. 2004;328(7442):741–2. https://doi.org/10.1136/bmj.328.7442.741 .
doi: 10.1136/bmj.328.7442.741
pubmed: 15044290
pmcid: 381323
von Mach MA, Gauer M, Meyer S, et al. Antidiabetic medications in overdose: a comparison of the inquiries made to a regional poisons unit regarding original sulfonylureas, biguanides and insulin. Int J Clin Pharmacol Ther. 2006;44(2):51–6. https://doi.org/10.5414/cpp44051 .
doi: 10.5414/cpp44051
Lustman PJ, Griffith LS, Freedland KE, et al. Cognitive behavior therapy for depression in type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med. 1998;129(8):613–21. https://doi.org/10.7326/0003-4819-129-8-199810150-00005 .
doi: 10.7326/0003-4819-129-8-199810150-00005
pubmed: 9786808
Bogner HR, Morales KH, de Vries HF, et al. Integrated management of type 2 diabetes mellitus and depression treatment to improve medication adherence: a randomized controlled trial. Ann Fam Med. 2012;10(1):15–22. https://doi.org/10.1370/afm.1344 .
doi: 10.1370/afm.1344
pubmed: 22230826
pmcid: 3262455
Markowitz SM, Gonzalez JS, Wilkinson JL, et al. A review of treating depression in diabetes: emerging findings. Psychosomatics. 2011;52(1):1–18. https://doi.org/10.1016/j.psym.2010.11.007 .
doi: 10.1016/j.psym.2010.11.007
pubmed: 21300190
pmcid: 3043600
Georgiades A, Zucker N, Friedman KE, et al. Changes in depressive symptoms and glycemic control in diabetes mellitus. Psychosom Med. 2007;69(3):235–41. https://doi.org/10.1097/PSY.0b013e318042588d .
doi: 10.1097/PSY.0b013e318042588d
pubmed: 17420441
Steed L, Cooke D, Newman S. A systematic review of psychosocial outcomes following education, self-management and psychological interventions in diabetes mellitus. Patient Educ Couns. 2003;51(1):5–15. https://doi.org/10.1016/s0738-3991(02)00213-6 .
doi: 10.1016/s0738-3991(02)00213-6
pubmed: 12915275
Wang MY, Tsai PS, Chou KR, et al. A systematic review of the efficacy of non-pharmacological treatments for depression on glycaemic control in type 2 diabetics. J Clin Nurs. 2008;17(19):2524–30. https://doi.org/10.1111/j.1365-2702.2008.02301.x .
doi: 10.1111/j.1365-2702.2008.02301.x
pubmed: 18808619
Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry. 2007;64(10):1123–31. https://doi.org/10.1001/archpsyc.64.10.1123 .
doi: 10.1001/archpsyc.64.10.1123
pubmed: 17909124
National Institute for Health and Care Excellence. Schizophrenia: core intervention in the treatment and management of schizophrenia in adults in primary and secondary care. 2008. http://www.nice.org.uk/guidance/index.jsp?action=download&o=42139 . Zugegriffen: 12. Aug. 2015.
Siskind DJ, Russell AW, Gamble C, Winckel K, Mayfield K, Hollingworth S, et al. Treatment of clozapine-associated obesity and diabetes with exenatide in adults with schizophrenia: a randomized controlled trial (CODEX). Diabetes Obes Metab. 2018;20(4):1050–5.
doi: 10.1111/dom.13167
pubmed: 29194917
Larsen JR, Vedtofte L, Jakobsen MSL, Jespersen HR, Jakobsen MI, Svensson CK, et al. Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine- or olanzapine-treated patients with schizophrenia spectrum: a randomized clinical trial. JAMA Psychiatry. 2017;74(7):719–28.
doi: 10.1001/jamapsychiatry.2017.1220
pubmed: 28601891
pmcid: 5710254
Holt RIG. Association between antipsychotic medication use and diabetes. Curr Diab Rep. 2019;19:96. https://doi.org/10.1007/s11892-019-1220-8 .
doi: 10.1007/s11892-019-1220-8
pubmed: 31478094
pmcid: 6718373
Long B, Lentz S, Koyfman A, Gottlieb M. Euglycemic diabetic ketoacidosis: etiologies, evaluation, and management. Am J Emerg Med. 2021;44:157–60. https://doi.org/10.1016/j-ajem.2021.02.015 .
doi: 10.1016/j-ajem.2021.02.015
pubmed: 33626481